Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography (SonR-ECHO)

MicroPort

Status

Completed

Conditions

Heart Failure

Treatments

Device: SonR CRT Optimization 'On'

Device: SonR CRT Optimization 'Off'

Study type

Interventional

Funder types

Industry

Identifiers

NCT01869062

ICSY01

Details and patient eligibility

About

The main objective of the SONR-ECHO trial is to demonstrate that optimization of CRT parameters by SonR technology is able to increase the rate of CRT-D responders, based on significant LV reverse remodeling, as compared to Standard of Care settings.

This study will also evaluate the effectiveness of CRT-D SonR system as compared to Standard of care (SoC) programming methods in providing appropriate LV filling, as expected from the Ritter method.

Full description

This study will evaluate the effectiveness of CRT-D SonR system as compared to SoC programming methods to:

Increase the rate of patients responding to CRT
Provide appropriate hemodynamic cardiac effect, as expected from the Ritter method.

The identification of CRT responders, as defined by echocardiography, generally refers to a significant reduction of the LV End-Systolic Diameter (LVESD) and/or LVESV during Follow-Up (FUp).

Patients will be considered as responders to CRT if their LVESV decreased by > 15% after 6 months of CRT therapy as compared to baseline. The percentage of CRT responders will be compared between the two study arms.

SoC is defined as the standard CRT system programming/optimization method currently used by physicians in study centers and any method may be used in the study if considered as routine practice in the study center.

Enrollment

348 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Eligible for implantation of a CRT-D device according to published relevant ESC and CCS guidelines ;
In Sinus Rhythm;
Have reviewed, signed and dated an informed consent

Exclusion criteria

Previous implant with a pacemaker, an Implantable Cardioverter-Defibrillator or a CRT device (except upgrade from single chamber ICD with a fully functional defibrillation lead not under recall or surveillance);
Persistent atrial arrhythmias (or cardioversion for Atrial Fibrillation) within the past month;
Ventricular tachyarrhythmia secondary to reversible causes such as acute myocardial infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;
Incessant ventricular tachyarrhythmia;
Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous Transluminal Coronary Angioplasty (PTCA) within the past 4 weeks;
Correctable valvular disease that is the primary cause of heart failure;
Mechanical heart valve or indication for valve repair or replacement;
Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months);
Post heart transplant (patients who are waiting for a heart transplant are allowed in the study);
Already included in another clinical study that could confound the results of this study;
Life expectancy less than 1 year;
Inability to understand the purpose of the study;
Unavailability for scheduled follow-up or refusal to cooperate;
Sensitivity to 1 mg Dexamethasone Sodium Phosphate (DSP);
Age of less than 18 years;
Pregnancy;
Drug addiction or abuse;
Under guardianship